Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific Opens New Biomarker Translational Center

Published: Wednesday, September 07, 2011
Last Updated: Wednesday, September 07, 2011
Bookmark and Share
Goal is to accelerate MS-based biomarker discovery and its translation into development of routine clinical assays.

Thermo Fisher Scientific Inc., has announced at the Human Proteome Organization (HUPO) 2011 World Congress the establishment of a new Biomarker Translational Center (BT Center).

The purpose of the BT Center is to accelerate mass spectrometry (MS)-based biomarker discovery research and its translation into the development of routine clinical assays for subsequent commercialization.

Based in Cambridge, Mass., the BT Center combines advanced expertise from across Thermo Fisher including its B•R•A•H•M•S product line and the team at the Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) Center.

“Through the vertical integration with the unique talent in MS-based biomarker discovery and high-throughput quantitative assay development at BRIMS, we aim to expand our pipeline of new protein and peptide biomarkers with potential as clinical assays,” said Bruno Darbouret, director of research and development for B•R•A•H•M•S Biomarkers at Thermo Fisher.

Darbouret continued, “Ultimately, this development effort will speed the commercialization of diagnostic tests that address life threatening diseases.”

Thermo Fisher, already a leading provider of specialty in-vitro diagnostic tests based on its patented Thermo Scientific B•R•A•H•M•S biomarkers, understands clinical market needs and will apply core strengths in diagnostics development, validation and commercialization to define the disease areas of focus for the BT Center.

The company’s well-established relationships with clinical researchers will provide access to clinical partners and patient samples for biomarker discovery and validation studies using B•R•A•H•M•S Biomarkers.

For the disease areas chosen, the BRIMS Center will apply its competencies in quantitative MS biomarker discovery and multiplexed selected reaction monitoring (SRM) assay development to identify putative biomarkers and their clinically relevant isoforms.

Subsequently it will develop robust, reproducible, targeted MS-based assays appropriate for the validation of putative biomarkers and ultimately for the clinical diagnostics market.

Thermo Fisher will own all intellectual property around the biomarkers and assays, and it will commercialize the assays as clinical diagnostic products and services after obtaining all requisite regulatory approvals.

“Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine,” said Bryan Krastins, group leader, BT Center.

Krastins continued, “Bridging this gap requires high-level competence in MS-based biomarker discovery and routine assay development for biomarker verification and validation. Understanding clinician and patient needs and having extensive experience in clinical validation are also essential to the transformation of novel tests into clinical routine assays. The new BT Center integrates all the capabilities needed to speed the clinical assay development pipeline from biomarker discovery to clinical assay development and validation.”

The Thermo Scientific B•R•A•H•M•S product line features a range of diagnostic test procedures to improve the diagnosis and treatment of life-threatening diseases, using patented biomarkers to bring about medically and economically superior diagnostic know-how for patients and users.

Thermo Scientific B•R•A•H•M•S products are used in more than 60 countries around the world.
Located in Cambridge, Mass., the BRIMS Center develops methodologies and applications for protein biomarker identification and verification.

Equipped with a full complement of Thermo Scientific mass spectrometers, and staffed by a team of scientists with expertise in mass spectrometry, protein techniques and informatics, the BRIMS Center also develops leading software tools for proteomic research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Scientific to Acquire Life Technologies Corporation
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.
Monday, April 15, 2013
Thermo Fisher Scientific Facilities Achieve ISO 13485 Certification
The facilities in San Jose, CA and Franklin, MA have achieved the internationally recognized standard of quality management for the design and manufacture of medical devices.
Thursday, April 04, 2013
Thermo Fisher Scientific Reports Q3 Revenue and EPS Results
Revenue increased 5% to a record $3.09 billion for the third quarter with adjusted operating income rising 5% to $576 million.
Wednesday, October 24, 2012
Thermo Scientific Elects New Director to Board
Appointment of C. Martin Harris to Company’s board of directors.
Monday, March 26, 2012
Thermo Fisher Scientific Introduces Unity Lab Services
The new offering combines product and laboratory support services to create a single solution for customers to optimize productivity and reduce their total cost of laboratory operations.
Monday, January 09, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Genetic Test Could Improve Blood Cancer Treatment
Testing for genetic risk factors could improve treatment for myeloma – a cancer of the blood and bone marrow – by helping doctors identify patients at risk of developing more aggressive disease.
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!